Table 4 Univariable and multivariable linear regression analyses of factors associated with overall satisfaction with medication (n = 78)
Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
B (95% CI) | p-value | B (95% CI) | p-value | |
Age | 0.019 (− 0.04;0.08) | 0.55 | – | – |
Gender | −0.97 (−2.6;0.6) | 0.25 | – | – |
Expectations effectiveness | 0.54 (−0.15;1.2) | 0.12 | – | – |
Expectations side-effects | −0.10 (− 0.85;0.65) | 0.79 | – | – |
FVC % predicted | 0.004 (−0.02;0.03) | 0.76 | – | – |
DLCO % predicted | 0.008 (−0.02;0.04) | 0.60 | ||
Change in FVC % predicted* | 0.05 (−0.005;0.01) | 0.079 | 0.026 (−0.05;0.10) | 0.64 |
Change in DLCO % predicted* | −0.04 (− 0.08;0.01) | 0.11 | – | – |
Antifibrotic drug | 0.24 (−0.62;1.1) | 0.58 | – | – |
VAS - cough | −0.23 (− 0.39;-0.07) | 0.005 | ||
VAS – dyspnea | −0.41 (− 0.56;-0.26) | < 0.001 | ||
VAS - general complaints | 0.36 (0.15;0.57) | 0.001 | 0.04 (−0.34;0.42) | 0.84 |
HADS – anxiety score | −0.30 (− 0.47;-0.14) | 0.001 | − 0.23 (− 0.63;0.17) | 0.24 |
HADS – depression score | − 0.24 (− 0.35;-0.13) | < 0.001 | −0.01 (− 0.29;0.28) | 0.95 |
Experiences effectiveness | 1.2 (0.6;1.75) | < 0.001 | 0.95 (0.22;1.67) | 0.01 |
Experiences side-effects | −0.53 (− 0.87;-0.18) | 0.003 | 0.07 (− 0.67;0.82) | 0.84 |
Experiences ease of use | −0.99 (−1.8;-0.17) | 0.019 | −0.34 (−1.99;1.31) | 0.68 |
Severity score side-effects | −0.07 (− 0.11;− 0.03) | 0.001 | -0.03 (− 0.11;0.052) | 0.49 |